ArticleJournal of medical cases2022
Remimazolam for Sedation During Upper Gastrointestinal Endoscopy in an Adolescent.
Article in Journal of medical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Advantages of Remimazolam in Pediatric Anesthesia: A Narrative Review.Children (Basel, Switzerland) · 2026Review
- Clinical indications and outcomes of pediatric gastrointestinal endoscopy in a resource-limited healthcare system: Findings from the first multicenter study.SAGE open medicine · 2026Article
- Remimazolam Use in Awake Craniotomy for Patient with Morbid Obesity and Recurrent Glioma.The American journal of case reports · 2025Article
- Involvement of anesthesiologists in pediatric sedation and analgesia outside the operating room in Japan: is it too late, or is there still time?Journal of anesthesia · 2025Review
- Comparison of remimazolam and midazolam for sedation during colonoscopy in Japanese patients: A propensity score matching analysis.DEN open · 2025Article
- Remimazolam's clinical application and safety: A signal detection analysis based on FAERS data and literature support.PloS one · 2025Article
- Comparative Study of Remimazolam and Midazolam During Sedated Upper Gastrointestinal Endoscopy: A Propensity Score Matching Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- The application of gastrointestinal endoscopy in children: a narrative review.Frontiers in pediatrics · 2025Review
- Remimazolam for sedation in gastrointestinal endoscopy: A comprehensive review.World journal of gastrointestinal endoscopy · 2024Review
- Clinical Application and Research Progress of Remimazolam for Pediatric Patients.Drug design, development and therapy · 2024Review
- Efficacy and safety of remimazolam besylate and ciprofol in painless gastrointestinal endoscopy in the elderly.Acta cirurgica brasileira · 2024Article
- Up-to-date literature review and issues of sedation during digestive endoscopy.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2023Review
- Remimazolam for Sedation During Fiberoptic Intubation in an Adolescent.Journal of medical cases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remimazolam is a short-acting benzodiazepine that has recently received approval from the US Food and Drug Administration (FDA) for procedural sedation in adults. Similar to other benzodiazepines such as midazolam, remimazolam has sedative, anxiolytic, and amnestic properties. Rapid metabolism by plasma esterases results in a half-life of 5 - 10 min and a limited context sensitive half-life. Preliminary data from adult studies have demonstrated favorable hemodynamic stability, no pain on injection, and limited impact on ventilatory function. To date, its use as the primary agent for procedural sedation in pediatric-aged patients has been limited, as previous published reports of its use have detailed its administration as an adjunct to general anesthesia. We report anecdotal experience with the use of remimazolam for procedural sedation during an upper gastrointestinal endoscopy in a 15-year-old adolescent with multiple drug and food allergies. The role of remimazolam in procedural sedation is discussed, previous reports of its use in pediatric-aged patients are reviewed, and dosing algorithms are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.